Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1

Frontiers in Immunology(2021)10.3389/fimmu.2020.531910Source: DataRank Database

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1 is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.32)OA: goldTopics (51)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Raul M. Torres ORCID,Divij Mathew ORCID

Live enrichment

PubMed:33584637 PMC:PMC7873449 OpenAlex:https://openalex.org/W3122323246

NIAID NIH HHS

Grant: T32 AI007405

NIAID NIH HHS

Grant: R01 AI143261

National Institutes of Health

Grant: 5T32AI007405-17

TRAINING PROGRAM IN IMMUNOLOGY

National Institutes of Health

Grant: 5R01AI143261-05

Lysophosphatidic Acid Regulation of CD8 T cell activation and function

National Institute of Allergy and Infectious Diseases

Cancer League of Colorado

FWCI

1.32

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.531910/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.531910/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.531910/full

journalhttps://doi.org/10.3389/fimmu.2020.531910

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33584637

Fields of Study

Immune Cell Function and InteractionImmune cells in cancerPhagocytosis and Immune Regulation0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

AnimalsHumansInflammationLysophospholipidsNeoplasm ProteinsNeoplasmsSignal TransductionCD8-Positive T-LymphocytesTumor EscapeReceptors, Lysophosphatidic AcidCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Keywords

Immune systemLysophosphatidic acidImmune checkpointSignal transductionCancer researchImmunologyReceptorBiologyCancer immunotherapyT cellImmune toleranceTumor microenvironmentImmunotherapyCell biologyBiochemistryCancerCd8 T CellInhibitory Receptor And LigandLysophophatidic AcidLpar5InflammationProgrammed Cell Death 1 ReceptorRC581-607CD8-Positive T-LymphocytesNeoplasm ProteinsNeoplasmsAnimalsHumansCTLA-4 AntigenTumor EscapeImmunologic diseases. AllergyLysophospholipidsReceptors, Lysophosphatidic Acid

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1

FAIR Checklist

Authors (2)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)